A Study to Evaluate the Pharmacokinetics of HSK7653 in Subjects With Renal Impairment

Summary

This is an open-label, single-dose study to evaluate the pharmacokinetics, pharmacodynamics and safety of HSK7653 in subjects with mild, moderate, severe renal impairment and subjects with kidney failure compared to the matched control subjects with normal renal function.

Timeline

Start

2022-08-04

Primary completion

2022-10-23

Completion

2022-10-26

Publications

• Shi D, Chen L, Li G, Wu N, Zhang F, Wang X, Mu N, Chen X, Yang X, Lu J, Lu Y, Wang M, Zhang D. Pharmacokinetics, Pharmacodynamics, and Safety of Single Dose HSK7653 Tablets in Chinese Subjects with Normal or Impaired Renal Function. Clin Pharmacokinet. 2024 Feb;63(2):227-239. doi: 10.1007/s40262-023-01333-4. Epub 2024 Jan 6.

Drugs

Indications